IFRX

InflaRx N.V. (IFRX) | Rumor.io

InflaRx

IFRX

Attention (50-day avg)0%

Attention rank (50-day avg)#1,353

Bullish sentiment (50-day avg)67%

Price to earnings ratio-2.65

Market capitalization268.2M

Earnings per share-0.57

Dividend yield (TTM)—

Revenue (annual)29.3K

Net income (annual)-45.6M

Social

What share of all stock conversation is about IFRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0.01% +0

Sep 21

InflaRx N.V. (IFRX) faces regulatory pressure, with the EU authorization for avacopan withdrawn in August and Switzerland planning revocation due to GCP breaches and ADVOCATE data issues.
New real-world data suggests avacopan was associated with lower severe-infection risk and lower prednisolone exposure in AAV patients, but no significant relapse difference.
InflaRx has a broader pipeline, including izicopan (oral C5aR inhibitor) for HS, AAV, renal diseases, and additional inflammatory diseases, as well as vilobelimab (anti-C5a antibody) for AAV and potential European regulatory opportunity.

Generated by AI

Sentiment

Of the messages about IFRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	60%	20.69% -29.31	61.59% -10.59	84.24% -0.71
Bearish	40%	79.31% +29.31	38.41% +10.59	15.76% +0.71

Bullish· May 8

InflaRx N.V. ($IFRX) has a significant revenue potential of $3.8 billion, with individual market segments reaching $1.3 billion, $1.0 billion, and $1.5 billion.
The company's market capitalization is relatively low, around $6.79 billion, which could lead to a stock price of $27 if it reaches a market capitalization of $4 billion.
InflaRx N.V. ($IFRX) has a strong potential for growth, with a market size projected to reach $27.5 billion by 2034, and a current market size of $13.7 billion in 2024.

Bearish· May 8

$IFRX's market capitalization of $200 million is too small in today's market, and it needs to settle in the $1 billion range.
The company's focus on AAV-neutrophils as an investment is promising, but the $150 million funding round is not sufficient to tap into the $1.3 billion market potential.
Shorts are targeting $IFRX, and the stock's steady chart is not immune to bearish attacks, with some analysts predicting a decline in the stock's price.

Generated by AI

Topics

Of the messages about IFRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	77.78%	88.61%	8.55%
Technical Analysis	100%	22.22%	6.33%	1.54%
Macro	0%	0%	1.27%	87.59%
Controversies	0%	0%	0%	0.19%
Analysts	0%	0%	3.8%	2%
Earnings	0%	0%	0%	0.13%

Analysts· Apr 6

Raymond James analyst Steven Seedhouse raised the price target on InflaRx to $25 from $8 and maintained a Strong Buy rating, citing the FDA's emergency use authorization for Gohibic in critically ill COVID-19 patients.
Analysts at Raymond James, Guggenheim Partners, and HC Wainwright have upgraded or maintained a Strong Buy rating on InflaRx, with price targets ranging from $8 to $25, citing potential sales opportunities for Gohibic in the COVID-19 market.
The average analyst rating for InflaRx stock is "Buy", with a consensus of 78% from 12 analysts, indicating that analysts believe the stock is likely to outperform the market over the next twelve months.

Announcements· May 6

InflaRx N.V. (IFRX) announced the advancement of its oral C5a inhibitor izicopan in ANCA-associated vasculitis and other complement-mediated kidney diseases.
The company intends to develop izicopan in ANCA-associated vasculitis, with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseases.
InflaRx priced a $150 million underwritten offering of ordinary shares, with 75 million shares sold at $2.00, to fund pipeline activities and working capital.

Technical Analysis· Nov 10

The $IFRX price has cleared the $2.00 level and is above its 20SMA, 50SMA, and 200SMA, with a relative strength index (RSI) below 50 indicating room for further growth.
The stock has a strong relative volume and liquidity, with a 58% increase in price on 25M+ volume, and is breaking out with a massive volume surge and an RSI surge.
The $IFRX chart is turning bullish, with a potential target area around $2.40, and a near bull cross on the MACD, indicating a possible upward trend.

Generated by AI

Community

Of the messages about IFRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	96.88%	96.21%	34.05%
Newcomers	0%	3.13%	3.79%	65.95%

Regulars· Sep 21

The EU authorization for avacopan was withdrawn in August 2026, and Switzerland plans to revoke it by November 30, 2026, due to GCP breaches and ADVOCATE data issues.
New real-world data for avacopan showed a lower severe-infection risk and lower prednisolone exposure in AAV patients, but no significant difference in relapse rates.
Regulatory authorities in Germany and the UK have reacted to the new data, with Germany revoking its benefit assessment and the UK suspending avacopan for new patients, with a planned withdrawal by March 2027.

Newcomers· May 6

Newcomers to $IFRX are focusing on the asset's significant price movement, with one post noting a 26.65% increase in the last 24 hours.
The recent $150M offering of 75M shares at $2.00 is a major concern for newcomers, with one post highlighting the heavy dilution and potential for a gap down at open.
Newcomers are also discussing the asset's pipeline advancement, with one post mentioning the potential for a catalyst in the form of a $150M offering and pipeline advancement in ANCA vasculitis.

Generated by AI

News

Needham Initiates InflaRx at Buy With $8 Price Target

InflaRx N.V (IFRX) has an average rating of buy and mean price target of $7.92, according to analyst

16d agoYahoo Finance

InflaRx at H.C. Wainwright conference: renal pivot takes center stage

16d agoInvesting.com

InflaRx at Cantor conference: renal pivot gains urgency

20d agoInvesting.com

InflaRx Announces Participation in September Investor Conferences

Jena, Germany, Aug. 20, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in two investor conferences in September 2026. Details are as follows: Cantor Global Healthcare Conference 2026September 9 - 11, 2026 in New York, NYFireside chat on September 9th at 3:20 PM ET InflaRx will also conduct one-on-one investor meetings on September 9th. A link to vie

1mo agoYahoo Finance

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as plannedInitiated feasibility assessment for broadened strategy for AAV in Europe Reported new pre-clinical data supporting the safety and differentiation of izicopan as a next-generation oral inhibitor of C5aRPharmacokinetic (PK) bridging study in China expected to start late this year, with a goal to accelerate izicopan proof-of-concept studies in additional inflamma

1mo agoYahoo Finance

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

Jena, Germany, July 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that the Company will report its second quarter 2026 financial and operating results on August 6, 2026, before the market opens. No conference call is planned. About InflaRx N.V. InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprieta

2mo agoYahoo Finance

Also Discussed

Investors talking about IFRX also mention

#	Name	Attention
1	Legacy Education Inc.LGCY	0%new
2	Immunic, Inc.IMUX	0%0
3	Xenetic Biosciences, Inc.XBIO	0%new
4	TEDU - TCTM Kids IT Education Inc.	——
5	MYOV - Myovant Sciences Ltd.	——
6	Bridgeline Digital IncBLIN	0%new
7	Bio-Path Holdings Inc.BPTH	0%0
8	Nanoviricides Inc.NNVC	0%0
9	OBLN - Obalon Therapeutics, Inc.	——
10	RACY - Relativity Acquisition Corp.	——

InflaRx N.V.

Healthcare
Biotechnology

InflaRx N.V. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing anti-inflammatory therapies that target the complement system, particularly the C5a and C5aR pathways. The company’s portfolio centers on proprietary antibody and small-molecule programs designed to address autoimmune and other inflammatory diseases through precise modulation of immune signaling. Its current pipeline includes vilobelimab, an intravenously administered anti-C5a antibody, and an oral C5aR inhibitor in development for inflammatory indications. InflaRx serves the biotechnology and healthcare sectors, with research and operational activities in Germany and the United States. The company’s work is centered on advancing novel treatments for severe inflammatory conditions where targeted complement inhibition may play an important therapeutic role.

Website

Location

Winzerlaer Str. 2

Jena, 07745

Germany

Social

What share of all stock conversation is about IFRX?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0.01% +0

Sep 21

InflaRx N.V. (IFRX) faces regulatory pressure, with the EU authorization for avacopan withdrawn in August and Switzerland planning revocation due to GCP breaches and ADVOCATE data issues.
New real-world data suggests avacopan was associated with lower severe-infection risk and lower prednisolone exposure in AAV patients, but no significant relapse difference.
InflaRx has a broader pipeline, including izicopan (oral C5aR inhibitor) for HS, AAV, renal diseases, and additional inflammatory diseases, as well as vilobelimab (anti-C5a antibody) for AAV and potential European regulatory opportunity.

Generated by AI

Sentiment

Of the messages about IFRX that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	60%	20.69% -29.31	61.59% -10.59	84.24% -0.71
Bearish	40%	79.31% +29.31	38.41% +10.59	15.76% +0.71

Bullish· May 8

InflaRx N.V. ($IFRX) has a significant revenue potential of $3.8 billion, with individual market segments reaching $1.3 billion, $1.0 billion, and $1.5 billion.
The company's market capitalization is relatively low, around $6.79 billion, which could lead to a stock price of $27 if it reaches a market capitalization of $4 billion.
InflaRx N.V. ($IFRX) has a strong potential for growth, with a market size projected to reach $27.5 billion by 2034, and a current market size of $13.7 billion in 2024.

Bearish· May 8

$IFRX's market capitalization of $200 million is too small in today's market, and it needs to settle in the $1 billion range.
The company's focus on AAV-neutrophils as an investment is promising, but the $150 million funding round is not sufficient to tap into the $1.3 billion market potential.
Shorts are targeting $IFRX, and the stock's steady chart is not immune to bearish attacks, with some analysts predicting a decline in the stock's price.

Generated by AI

Topics

Of the messages about IFRX that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	77.78%	88.61%	8.55%
Technical Analysis	100%	22.22%	6.33%	1.54%
Macro	0%	0%	1.27%	87.59%
Controversies	0%	0%	0%	0.19%
Analysts	0%	0%	3.8%	2%
Earnings	0%	0%	0%	0.13%

Analysts· Apr 6

Raymond James analyst Steven Seedhouse raised the price target on InflaRx to $25 from $8 and maintained a Strong Buy rating, citing the FDA's emergency use authorization for Gohibic in critically ill COVID-19 patients.
Analysts at Raymond James, Guggenheim Partners, and HC Wainwright have upgraded or maintained a Strong Buy rating on InflaRx, with price targets ranging from $8 to $25, citing potential sales opportunities for Gohibic in the COVID-19 market.
The average analyst rating for InflaRx stock is "Buy", with a consensus of 78% from 12 analysts, indicating that analysts believe the stock is likely to outperform the market over the next twelve months.

Announcements· May 6

InflaRx N.V. (IFRX) announced the advancement of its oral C5a inhibitor izicopan in ANCA-associated vasculitis and other complement-mediated kidney diseases.
The company intends to develop izicopan in ANCA-associated vasculitis, with a secondary goal of establishing rapid proof of concept in additional life-threatening renal diseases.
InflaRx priced a $150 million underwritten offering of ordinary shares, with 75 million shares sold at $2.00, to fund pipeline activities and working capital.

Technical Analysis· Nov 10

The $IFRX price has cleared the $2.00 level and is above its 20SMA, 50SMA, and 200SMA, with a relative strength index (RSI) below 50 indicating room for further growth.
The stock has a strong relative volume and liquidity, with a 58% increase in price on 25M+ volume, and is breaking out with a massive volume surge and an RSI surge.
The $IFRX chart is turning bullish, with a potential target area around $2.40, and a near bull cross on the MACD, indicating a possible upward trend.

Generated by AI

Community

Of the messages about IFRX, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	96.88%	96.21%	34.05%
Newcomers	0%	3.13%	3.79%	65.95%

Regulars· Sep 21

The EU authorization for avacopan was withdrawn in August 2026, and Switzerland plans to revoke it by November 30, 2026, due to GCP breaches and ADVOCATE data issues.
New real-world data for avacopan showed a lower severe-infection risk and lower prednisolone exposure in AAV patients, but no significant difference in relapse rates.
Regulatory authorities in Germany and the UK have reacted to the new data, with Germany revoking its benefit assessment and the UK suspending avacopan for new patients, with a planned withdrawal by March 2027.

Newcomers· May 6

Newcomers to $IFRX are focusing on the asset's significant price movement, with one post noting a 26.65% increase in the last 24 hours.
The recent $150M offering of 75M shares at $2.00 is a major concern for newcomers, with one post highlighting the heavy dilution and potential for a gap down at open.
Newcomers are also discussing the asset's pipeline advancement, with one post mentioning the potential for a catalyst in the form of a $150M offering and pipeline advancement in ANCA vasculitis.

Generated by AI

InflaRx

Social

Sep 21

Bullish· May 8

Bearish· May 8

Analysts· Apr 6

Announcements· May 6

Technical Analysis· Nov 10

Regulars· Sep 21

Newcomers· May 6

Needham Initiates InflaRx at Buy With $8 Price Target

InflaRx at H.C. Wainwright conference: renal pivot takes center stage

InflaRx at Cantor conference: renal pivot gains urgency

InflaRx Announces Participation in September Investor Conferences

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

Also Discussed

InflaRx N.V.

Company Information

Location

Needham Initiates InflaRx at Buy With $8 Price Target

InflaRx at H.C. Wainwright conference: renal pivot takes center stage

InflaRx at Cantor conference: renal pivot gains urgency

InflaRx Announces Participation in September Investor Conferences

InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones

InflaRx to Report Second Quarter 2026 Results on August 6, 2026

Also Discussed

Social

Sep 21

Bullish· May 8

Bearish· May 8

Analysts· Apr 6

Announcements· May 6

Technical Analysis· Nov 10

Regulars· Sep 21

Newcomers· May 6